BerGenBio ASA (BRRGF) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
BerGenBio ASA announces the departure of CEO Martin Olin, who has led the company through strategic transitions and the development of its lead drug candidate, bemcentinib. The Board of Directors is now initiating a search for a new CEO to continue advancing the company’s pipeline. BerGenBio, a biopharmaceutical company focused on developing AXL inhibitors for severe diseases, remains poised for an exciting future as Olin commits to following its progress.
For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.
